Tandem Diabetes Care (TNDM) Revenue Growth (3y) (2016 - 2026)

Tandem Diabetes Care (TNDM) Revenue Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 4.63%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 8.01%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 4.70%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 15.36%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn 10.52%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 17.14%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 2.92%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 0.73%
10 Tandem Diabetes Care 1.17 Bn 597.96 Mn 136.79 Mn 13.43%

Historic Data

Download Data
DateValue
Mar 31, 2026 13.43%
Dec 31, 2025 9.61%
Sep 30, 2025 6.81%
Jun 30, 2025 6.32%
Mar 31, 2025 10.05%
Dec 31, 2024 10.41%
Sep 30, 2024 10.74%
Jun 30, 2024 8.83%
Mar 31, 2024 10.77%
Dec 31, 2023 5.40%
Sep 30, 2023 14.52%
Jun 30, 2023 21.50%
Mar 31, 2023 20.04%
Dec 31, 2022 26.71%
Sep 30, 2022 29.28%
Jun 30, 2022 29.02%
Mar 31, 2022 38.65%
Dec 31, 2021 40.20%
Sep 30, 2021 57.17%
Jun 30, 2021 71.50%